New SDR400 CVD Reactor from GT Solar Increases Polysilicon Production

GT Solar International, Inc. (NASDAQ: SOLR), a global provider of polysilicon production technology, and sapphire and silicon crystalline growth systems and materials for the solar, LED and other specialty markets, today announced the SDR™400 next generation CVD reactor for the production of high purity polysilicon.

The SDR400 reactor can produce greater than 400 metric tons annually (MTA) of polysilicon. The new SDR400 also lowers electricity consumption by approximately 20 percent for each kilogram of polysilicon produced over the company’s previous generation reactor, the SDR300.

GT Solar SDR(TM)400 CVD reactor can produce greater than 400 MTA of high purity polysilicon

“Our new SDR400 CVD reactor further extends our polysilicon production technology leadership,” said Dave Keck, vice president and general manager of GT Solar’s polysilicon division. “Customers can produce 33 percent more polysilicon annually in the same footprint using approximately 20 percent less electricity for every kilogram of polysilicon produced. This lowers their cost of ownership and strengthens their competitive position.”

GT Solar also announced that it is partnering with German-based AEG Power Solutions to offer a new power supply developed by AEG, the Thryobox™ PI, that is designed to further enhance the output of the SDR400 reactor. The new power supply will be offered as an option to the standard SDR400 configuration and is targeted to increase annual polysilicon production to greater than 500 MTA. Current GT Solar customers using previous generation reactors will be able to upgrade these systems to take advantage of the expected increased annual production output.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.